This interview follows the interview with Sébastien Lasnier, CEO of LSL Neurosciences

Introduction

Pharmacist and Pharmacologist, Noelle Callizot is a recognized expert in France and abroad in the research and development of molecules for the treatment of neurodegenerative diseases (with a particular interest in the diseases of PARKINSON, ALZHEIMER and CHARCOT or SLA). For more than 20 years, she has enabled the pharmaceutical development of neuroactive molecules up to advanced clinical stages. Director of Pharmacology and Pharmaceutical Development for the listed company Phytopharm (Cambridge, UK) for 6 years, she led various programs in neurodegenerative diseases (Alzheimer's and Parkinson's) until their entry into phase 3. In addition, Noëlle Callizot is co-founder of 4 French biotechnology companies in the fields of contractual research, functional neurorehabilitation and screening of neuroactive molecules. She is also director of development for AlzProtect, and sits on the scientific board of numerous start-ups and biotechs in France and abroad. Noelle is also a permanent member of the scientific council of AFM-TELETHON, she chairs the association's pharmacology commission.

Dr Noëlle Callizot, you support the LSL Neurosciences project. Can you tell us about this project please?

The LSL project uses different concepts that are of particular interest to me. First of all, the use of molecules known in the field of neuroprotection and well described pharmacologically, this ensuring safety and tolerance. In addition, their clinical development is rapid since these molecules are already approved. On the other hand, the project is based on the combination of several of these approved molecules. In the neurodegenerative field where the mechanisms involved are multiple, it is now accepted that the treatments known as "disease modifiers" will be different at each phase of the disease, the combination of molecules makes it possible to partially answer this question

What is the future of LSL?

LSL's therapeutic strategy is based on the combination of molecules whose mechanisms of action are known to be involved in the processes of neuronal death and involved in Alzheimer's disease. The first clinical trials with this combination have shown very interesting and encouraging results. Further testing in a larger number of patients and further understanding of the mechanisms involved in the effect of this combination is absolutely necessary. The solution proposed by LSL could open a new therapeutic strategy in an area where no curative treatment has yet been approved.